{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:33:13Z","timestamp":1751275993286,"version":"3.41.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ando.2025.101733","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T22:56:42Z","timestamp":1745621802000},"page":"101733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"H\u00e9l\u00e8ne","family":"Lasolle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abir","family":"Al Ghuzlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Drui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Buffet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Segol\u00e8ne","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Godbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slimane","family":"Zerdoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Ciappuccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francoise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101733_bib0215","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101733_bib0220","doi-asserted-by":"crossref","first-page":"R499","DOI":"10.1530\/ERC-18-0574","article-title":"Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives","volume":"26","author":"Ceolin","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2025.101733_bib0225","doi-asserted-by":"crossref","first-page":"E698","DOI":"10.3390\/genes10090698","article-title":"Twenty-five years experience RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.ando.2025.101733_bib0230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EC-18-0157","article-title":"Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960\u20132014: a nationwide study","volume":"7","author":"Mathiesen","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2025.101733_bib0235","doi-asserted-by":"crossref","first-page":"e230319","DOI":"10.1530\/ERC-23-0319","article-title":"Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the United States, 2000\u20132020: a population-based retrospective cohort study","volume":"31","author":"Tao","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2025.101733_bib0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","article-title":"Management of advanced medullary thyroid cancer","volume":"4","author":"Hadoux","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2025.101733_bib0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ecl.2018.11.006","article-title":"Management of medullary thyroid cancer","volume":"48","author":"Viola","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2025.101733_bib0250","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamasurg.2017.3555","article-title":"Risk Factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma","volume":"153","author":"Kuo","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ando.2025.101733_bib0255","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1210\/clinem\/dgae214","article-title":"Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer","volume":"109","author":"Liu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101733_bib0260","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101733_bib0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.21.01329","article-title":"International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ando.2025.101733_bib0275","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2025.101733_bib0280","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.ando.2025.101733_bib0285","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101733_bib0290","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/thy.2023.0279","article-title":"Association of the genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study","volume":"34","author":"Xu","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101733_bib0295","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101733_bib0300","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1530\/ERC-18-0056","article-title":"Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis","volume":"25","author":"Vuong","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2025.101733_bib0305","doi-asserted-by":"crossref","first-page":"E2031","DOI":"10.1210\/jc.2012-2092","article-title":"Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon","volume":"97","author":"Boichard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101733_bib0310","doi-asserted-by":"crossref","first-page":"e1005467","DOI":"10.1371\/journal.pgen.1005467","article-title":"Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer","volume":"11","author":"Ji","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ando.2025.101733_bib0315","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ando.2025.101733_bib0320","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bulcan.2021.06.009","article-title":"Molecular genotyping in refractory thyroid cancers in 2021: when, how and why? A review from the TUTHYREF network","volume":"108","author":"de la Fouchardi\u00e8re","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ando.2025.101733_bib0325","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of tyrosine kinase inhibitors (TKIs) side effects in differentiated and medullary thyroid cancer patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101733_bib0330","first-page":"e240077","article-title":"Overview of management and therapeutic advances in medullary thyroid cancer","volume":"5","author":"Jara","year":"2025","journal-title":"Endocr Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0335","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0340","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0345","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0350","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000509457","article-title":"Benefits and limitations of TKIs in patients with medullary thyroid cancer: a systematic review and meta-analysis","volume":"10","author":"Efstathiadou","year":"2021","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2025.101733_bib0360","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101733_bib0365","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101733_bib0370","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/bph.14395","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ando.2025.101733_bib0375","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0380","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.18632\/oncotarget.23986","article-title":"RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases","volume":"9","author":"Romei","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ando.2025.101733_bib0385","doi-asserted-by":"crossref","first-page":"e2300053","DOI":"10.1200\/PO.23.00053","article-title":"Patterns of treatment failure after selective rearranged during transfection (RET) inhibitors in patients with metastatic medullary thyroid carcinoma","volume":"7","author":"Hadoux","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0390","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2017-01039","article-title":"Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma","volume":"102","author":"Cote","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101733_bib0395","doi-asserted-by":"crossref","first-page":"e3420","DOI":"10.1210\/clinem\/dgac222","article-title":"Pre- and post-operative circulating tumoral DNA in patients with medullary thyroid carcinoma","volume":"107","author":"Ciampi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101733_bib0400","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3109\/0284186X.2016.1157264","article-title":"Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?","volume":"55","author":"Marchand","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0405","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1089\/thy.2023.0144","article-title":"Alkylating agent-induced high tumor mutational burden in medullary thyroid cancer and response to immune checkpoint inhibitors: two case reports","volume":"33","author":"Moog","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101733_bib0410","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2025.101733_bib0415","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treatedwith pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2025.101733_bib0420","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:50:13Z","timestamp":1751028613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0003426625000526"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101733","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101733"}}